Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)”In the company’s words, NCT07160634 on ClinicalTrials.gov
- Tested for
- Duchenne Muscular Dystrophy
- Main trialPhase 3
- “This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing…”In the company’s words, NCT07160634 on ClinicalTrials.gov
Other drugs for Duchenne Muscular Dystrophy
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- DeramiocelCapricor Inc. · Phase 3
- SatralizumabRoche · Phase 2
- DS-5141bDaiichi Sankyo · Phase 2
Coming up1
- Jan 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jan 2029 | A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026